The mechanism of HAE suggests that antifibrinolytic agents, such as epsilon amino caproic acid (EACA) and tranexamic acid (TXA), may be potential therapeutic options for inhibiting the conversion of PLG/K311E to plasmin, thereby halting HAE progression and alleviating symptoms. This evidence concerns the gene PLG and hereditary angioedema.